About
Our Goals
Corventis is committed to improving clinical outcomes and lowering healthcare costs by enabling the early detection of cardiovascular events while allowing patients to maintain an active lifestyle. By combining medical device, wireless and information technologies, our patient and physician friendly solutions are designed with the goals of:
- Wirelessly connecting clinicians and patients while increasing patient compliance
- Providing focused and continuous visibility into cardiac health status
- Delivering exception-based, actionable information to guide clinical decisions
- Enabling seamless use by clinicians and patients across the globe
Our Accomplishments
Since our inception, we have made great strides in delivering on our commitment through a series of successful research, development, clinical, regulatory and commercial accomplishments including:
- Filing more than 70 patents in the United States and internationally for our technology and solutions
- Completion of the international, prospective, multi-center MUSIC (Multi-Sensor Monitoring in Congestive Heart Failure) program of clinical trials which enrolled 543 patients
- 510k clearance and CE Mark for the AVIVO® Mobile Patient Management System
- 510k clearance and CE Mark for the NUVANT® Mobile Cardiac Telemetry System
- Certification of the Corventis Monitoring Center as an Independent Diagnostic Testing Center (IDTF) by the Center for Medicare and Medicaid Services (CMS)
- Secured reimbursement for over 100M covered lives (Medicare, commercial payers) in the United States for use of the NUVANT Mobile Cardiac Telemetry System
- Recognition as a Technology Pioneer 2010 by the World Economic Forum and receipt of the President's Innovation Award from the American Telemedicine Association in 2010
Our Team
Our employees and advisors include experts in the medical device and information technology industries as well as leading physicians in the fields of clinical cardiology, electrophysiology and heart failure management. Privately held, we are backed by prominent venture capital firms Kleiner Perkins Caufield & Byers, Mohr Davidow Ventures, DAG Ventures and PTV Sciences.